HR020602 injection + fentanyl injection ； remifentanil injection
Phase 2CompletedDevelopment Stage
Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)
Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)
Jun 7, 2021 → Aug 15, 2023
About HR020602 injection + fentanyl injection ； remifentanil injection
HR020602 injection + fentanyl injection ； remifentanil injection is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol). The current trial status is completed. This product is registered under clinical trial identifier NCT04867343. Target conditions include Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol).
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04867343 | Phase 2 | Completed |
Competing Products
8 competing products in Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E3810 + E3810 + Teprenone | Eisai | Phase 2/3 | 65 |
| Rabeprazole + Rabeprazole | Eisai | Phase 2/3 | 65 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 77 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Phase 3 | 77 |
| Hib-CRM197 + Hib-TT | Novartis | Phase 3 | 77 |
| 13-valent Pneumococcal conjugate vaccine | Pfizer | Approved | 84 |
| Elinzanetant (BAY3427080) + Placebo | Bayer | Phase 3 | 74 |
| Tofersen | Biogen | Phase 3 | 74 |